TY - JOUR
T1 - Blood lymphocyte subsets identify optimal responders to IFN-beta in MS
AU - Alenda, Raquel
AU - Costa-Frossard, Lucienne
AU - Alvarez-Lafuente, Roberto
AU - Espejo, Carmen
AU - Rodríguez-Martín, Eulalia
AU - de la Maza, Susana Sainz
AU - Villarrubia, Noelia
AU - Río, Jordi
AU - Domínguez-Mozo, María I.
AU - Montalban, Xavier
AU - Álvarez-Cermeño, José C.
AU - Villar, Luisa M.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - © 2017, Springer-Verlag GmbH Germany. Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing–remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively. 9% of patients developed NAb. These antibodies were more frequent in patients receiving IFN-beta 1b than in those treated subcutaneous (p = 0.008) or intramuscular (p < 0.0001) IFN-beta 1a. No patient showing NAb remained NEDA during follow-up. Basal immunological variables are also associated with patient response. Percentages below 3% of CD19 + CD5 + cells (AUC 0.74, CI 0.63–0.84; OR 10.68, CI 3.55–32.15, p < 0.0001; Likelihood ratio 4.28) or above 2.6% of CD8 + perforin + T cells (AUC 0.79, CI 0.63–0.96; OR 6.11, CI 2.0–18.6, p = 0.0009; Likelihood ratio 5.47) increased the probability of achieving NEDA status during treatment. Basal blood immune cell subsets contribute to identify MS patients with a high probability of showing an optimal response to IFN-beta.
AB - © 2017, Springer-Verlag GmbH Germany. Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing–remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively. 9% of patients developed NAb. These antibodies were more frequent in patients receiving IFN-beta 1b than in those treated subcutaneous (p = 0.008) or intramuscular (p < 0.0001) IFN-beta 1a. No patient showing NAb remained NEDA during follow-up. Basal immunological variables are also associated with patient response. Percentages below 3% of CD19 + CD5 + cells (AUC 0.74, CI 0.63–0.84; OR 10.68, CI 3.55–32.15, p < 0.0001; Likelihood ratio 4.28) or above 2.6% of CD8 + perforin + T cells (AUC 0.79, CI 0.63–0.96; OR 6.11, CI 2.0–18.6, p = 0.0009; Likelihood ratio 5.47) increased the probability of achieving NEDA status during treatment. Basal blood immune cell subsets contribute to identify MS patients with a high probability of showing an optimal response to IFN-beta.
KW - Biomarkers
KW - Demyelinating diseases
KW - Lymphocytes
KW - Multiple sclerosis
U2 - 10.1007/s00415-017-8625-6
DO - 10.1007/s00415-017-8625-6
M3 - Article
SN - 0340-5354
VL - 265
SP - 24
EP - 31
JO - Journal of Neurology
JF - Journal of Neurology
IS - 1
ER -